Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ScripsAmerica, a provider of prescription, OTC and nutraceutical drugs, has completed the R&D phase for its RapiMed pain reliever for children.
Subscribe to our email newsletter
ScripsAmerica’s manufacturer is expected to begin production of the RapiMed formulations and make the product available for distribution during the first quarter of 2013.
ScripsAmerica CEO Bob Schneiderman RapiMed is a premium-quality children’s pain reliever that boasts flavor and utilizes a delivery technology that provides enhanced convenience.
"The children’s analgesic market has been in turmoil recently due to ongoing recalls of other major branded product lines along with many regulatory failures due to manufacturing from other types of pain relievers in tablet and liquid form," RapiMed added.
The RapiMed tablets, a solid-dose rapid-melt product, has leveraged the company’s patented technology and will be available in two doses and in two flavors, grape and bubblegum.